NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Formats Text Remove constraint Formats: Text Subjects United States Remove constraint Subjects: United States Copyright Public domain Remove constraint Copyright: Public domain

Search Results

5104. Testing of glycerin, propylene glycol, maltitol solution, hydrogenated starch hydrolysate, sorbitol solution, and other high-risk drug components for diethylene glycol and ethylene glycol: guidance for industry

5110. Cybersecurity in medical devices: refuse to accept policy for cyber devices and related systems under section 524B of the FD&C Act : guidance for industry and Food and Drug Administration staff

5113. Transition plan for medical devices that fall within enforcement policies issued during the coronavirus disease 2019 (COVID-19) public health emergency: guidance for industry, other stakeholders, and Food and Drug Administration staff

5114. Transition plan for medical devices issued emergency use authorizations (EUAs) related to coronavirus disease 2019 (COVID-19): guidance for industry, other stakeholders, and Food and Drug Administration staff

5115. Enforcement policy for face masks and barrier face coverings during the coronavirus disease (COVID-19) public health emergency: guidance for industry and Food and Drug Administration staff

5116. Enforcement policy for face shields, surgical masks, and respirators during the coronavirus disease (COVID-19) public health emergency: guidance for industry and Food and Drug Administration staff

5120. Compounding certain ibuprofen oral suspension products under section 503B of the Federal Food, Drug, and Cosmetic Act

5128. Long-term projections of health care spending and the implications for the federal budget: presentation at the 15th annual meeting of the OECD’s working party of parliamentary budget officials and independent fiscal institutions

5133. Budgetary effects of policies to modify or eliminate Medicaid’s institutions for mental diseases exclusion

5135. Non-clinical performance assessment of tissue containment systems used during power morcellation procedures: guidance for industry and Food and Drug Administration staff

5137. Implementation of acceptable full-length and abbreviated donor history questionnaires and accompanying materials for use in screening donors of blood and blood components: guidance for industry

5138. Recommendations for evaluating donor eligibility using individual risk-based questions to reduce the risk of human immunodeficiency virus transmission by blood and blood products: guidance for industry

5140. Presenting quantitative efficacy and risk information in direct-to-consumer (DTC) promotional labeling and advertisements: guidance for industry

5141. Alternative procedures for the manufacture of cold-stored platelets intended for the treatment of active bleeding when conventional platelets are not available or their use is not practical: guidance for industry

5144. Hydrogen peroxide-based contact lens care products: consumer labeling recommendations : premarket notification (510(k)) submissions : guidance for industry and Food and Drug Administration staff

5146. M7(R2) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk: guidance for industry

5147. Understanding coverage considerations for COVID-19 vaccines and treatments

5148. Updated national survey trends in telehealth utilization and modality (2021-2022)

5150. Social needs screening among non-federal acute care hospitals, 2022

5152. Use of telemedicine among office-based physicians, 2021

5154. Labs with questionably high billing for additional tests alongside COVID-19 tests warrant further scrutiny

5158. Zoonotic diseases: Federal actions needed to improve surveillance and better assess human health risks posed by wildlife : report to congressional committees

5159. Public health: Leading practices could help guide HHS reform efforts to address risk and improve preparedness : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

5161. Federal research: NIH could take additional actions to manage risks involving foreign subrecipients : report to congressional requesters

5165. Medicaid: CMS oversight and guidance could improve Recovery Audit Contractor program : report to congressional requesters

5166. USAID: Management improvements needed to better meet global health mission : report to the Chairman, Committee on Foreign Relations, U.S. Senate

5167. Indian Health Service: Actions needed to improve use of data on adverse events : report to congressional requesters

5169. Defense health care: Additional assessments needed to determine effects of active duty medical personnel reductions : report to congressional committees

5171. VA health care: Office of the Medical Inspector should strengthen oversight of recommendations and assess performance : report to congressional requesters

5172. Unwanted sexual behavior: improved guidance, access to care, and training needed to better address victims’ behavioral health needs : report to congressional requesters

5174. CBO’s 2023 long-term budget projections: presentation at the American Enterprise Institute : methodologies in fiscal, economic, and health spending projections

5180. Advancing primary prevention in human services. Opportunities for people with lived experience

5181. Advancing primary prevention in human services. Key considerations for policy designers and funding partners

5182. Advancing primary prevention in human services. Key considerations for administrators and practitioners

5183. Medicare Part B drugs: trends in spending and utilization, 2008-2021

5184. Medicare Part D enrollee out-of-pocket spending: recent trends and projected impacts of the Inflation Reduction Act

5185. Updated Medicare FFS telehealth trends by beneficiary characteristics, visit specialty, and state, 2019-2021

5190. CMS has opportunities to strengthen states’ oversight of Medicaid Managed Care Plans’ reporting of medical loss ratios

5192. During the initial COVID-19 response, HHS personnel who interacted with potentially infected passengers had limited protections

5197. Inaccuracies in Medicare’s race and ethnicity data hinder the ability to assess health disparities